BETA 002
Alternative Names: BETA-002Latest Information Update: 14 Jul 2025
At a glance
- Originator University of New South Wales
- Developer Filamon
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic macular oedema; Wet age-related macular degeneration
Most Recent Events
- 14 Jul 2025 Preclinical trials in Diabetic macular oedema in Australia (Ophthalmic), before July (Filamon website, July 2025)
- 14 Jul 2025 Preclinical trials in Diabetic macular oedema in Australia (PO), before July (Filamon website, July 2025)
- 14 Jul 2025 Preclinical trials in Wet age-related macular degeneration in Australia (Ophthalmic), before July (Filamon pipeline, July 2025)